LWM
AKBA icon

Laidlaw Wealth Management’s Akebia Therapeutics AKBA Stock Holding History

Laidlaw Wealth Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,195
Closed -$77K – 184
2020
Q1 		$77K Hold
10,195
– – 0.05% 146
2019
Q4 		$64K Buy
+10,195
New +$48.5K 0.04% 166

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Laidlaw Wealth Management's AKBA Position: Q2 2020 in Review

Laidlaw Wealth Management sold out of Akebia Therapeutics (AKBA) in Q2 2020, closing a stake of 10,195 shares — an estimated $77K sold.

Laidlaw Wealth Management first reported a position in AKBA in Q4 2019 and held it in 2 quarters. The position peaked at $77K in Q1 2020. 189 funds tracked by Wall St. Rank hold AKBA as of Q2 2020.

  • Laidlaw Wealth Management reported no remaining Akebia Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Laidlaw Wealth Management sold 10,195 Akebia Therapeutics shares in Q2 2020, an estimated $77K.
  • Laidlaw Wealth Management first reported a position in Akebia Therapeutics in Q4 2019 and held it in 2 quarters.
  • Laidlaw Wealth Management's Akebia Therapeutics position peaked at $77K in Q1 2020.
  • 189 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2020.

Based on Laidlaw Wealth Management's 13F filing for Q2 2020, filed 13 Aug 2020.